

# Lumito Selected for Business Sweden's CATALYST 2025 – Focusing on Expansion in the United Kingdom

**Lumito AB (publ) ("Lumito" or the "Company"), which has developed a solution for advanced tissue analysis based on upconverting nanoparticles (UCNPs), has been selected for Business Sweden's prestigious scale-up programme, Catalyst 2025. The programme brings together Sweden's most innovative and promising growth companies, with the aim of supporting commercial expansion in a market chosen by the Company.**

Lumito is one of three companies admitted to this year's Catalyst programme. By participating, the Company will gain access to specialised strategic support in marketing, market entry, networking, pitching opportunities to leading industry players, advisory services, and invitations to relevant events. The support provided through the programme corresponds to a value of approximately SEK 250,000.

Within the framework of Catalyst 2025, Lumito will focus on continuing its market introduction in the United Kingdom – a strategically important market for the Company's research platform, SCIZYS, and a market with a strong global position in pharmaceutical development, as well as a large number of leading Contract Research Organisations (CROs), which is a key segment for Lumito. The Company already collaborates with the UK-based CRO, Concept Life Sciences.

"Being selected for the Catalyst programme is a clear recognition of our international potential and, at the same time, a significant opportunity to accelerate our commercial establishment in the United Kingdom. It is a great honour to have been chosen in such strong competition, and we look forward to working closely with Business Sweden and their local experts to build business relationships and deepen collaborations in the UK market," says Sanna Wallenborg, CEO of Lumito.

Business Sweden's Catalyst programme offers strategic support for market development, partnerships, and business growth, with the aim of scaling up Swedish growth companies in selected international markets.

[Read more about the Catalyst scale-up programme.](#)

**For further information, please contact:**

---

Sanna Wallenborg, CEO Lumito  
E-mail: [sw@lumito.se](mailto:sw@lumito.se)  
Ph: +4670-870 01 68

**About Lumito**

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

**Attachments**

[Lumito Selected for Business Sweden's CATALYST 2025 – Focusing on Expansion in the United Kingdom](#)